{"Title": "A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer", "Year": 2020, "Source": "Clin. Cancer Res.", "Volume": "26", "Issue": 5, "Art.No": null, "PageStart": 1009, "PageEnd": 1016, "CitedBy": 11, "DOI": "10.1158/1078-0432.CCR-19-1638", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081125780&origin=inward", "Abstract": "\u00a9 2020 American Association for Cancer Research Inc.. All rights reserved.Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and carboplatin (G\u00feC) against second-line chemotherapy in women with measurable or detectable platinum-resistant ovarian cancer. Patients and Methods: Patients received either G\u00feC (guadecitabine 30 mg/m2 s.c. once-daily for 5 days and carboplatin) or treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) in 28-day cycles until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were RECIST v1.1 and CA-125 response rate, 6-month PFS, and overall survival (OS). Results: Of 100 patients treated, 51 received G\u00feC and 49 received TC, of which 27 crossed over to G\u00feC. The study did not meet its primary endpoint as the median PFS was not statistically different between arms (16.3 weeks vs. 9.1 weeks in the G\u00feC and TC groups, respectively; P \u00bc 0.07). However, the 6-month PFS rate was significantly higher in the G\u00feC group (37% vs. 11% in TC group; P \u00bc 0.003). The incidence of grade 3 or higher toxicity was similar in G\u00feC and TC groups (51% and 49%, respectively), with neutropenia and leukopenia being more frequent in the G\u00feC group. Conclusions: Although this trial did not show superiority for PFS of G\u00feC versus TC, the 6-month PFS increased in G\u00feC treated patients. Further refinement of this strategy should focus on identification of predictive markers for patient selection.", "AuthorKeywords": null, "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85081125780", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"19737542700": {"Name": "Oza A.M.", "AuthorID": "19737542700", "AffiliationID": "60008768, 60016849, 60014468", "AffiliationName": "Princess Margaret Cancer Centre, University Health Network, University of Toronto"}, "6701616188": {"Name": "Matulonis U.A.", "AuthorID": "6701616188", "AffiliationID": "60014334", "AffiliationName": "Dana-Farber Cancer Institute"}, "6604094111": {"Name": "Secord A.A.", "AuthorID": "6604094111", "AffiliationID": "60018749", "AffiliationName": "Duke Cancer Institute"}, "7005088929": {"Name": "Nemunaitis J.", "AuthorID": "7005088929", "AffiliationID": "60016240, 60021624", "AffiliationName": "University of Toledo, College of Medicine and Life Sciences"}, "7101826473": {"Name": "Roman L.D.", "AuthorID": "7101826473", "AffiliationID": "60022143", "AffiliationName": "USC Norris Comprehensive Cancer Center"}, "6507446693": {"Name": "Blagden S.P.", "AuthorID": "6507446693", "AffiliationID": "60026851", "AffiliationName": "University of Oxford"}, "55433897700": {"Name": "Banerjee S.", "AuthorID": "55433897700", "AffiliationID": "60017166", "AffiliationName": "Royal Marsden NHS Foundation Trust"}, "7201836300": {"Name": "McGuire W.P.", "AuthorID": "7201836300", "AffiliationID": "60002476", "AffiliationName": "Virginia Commonwealth University"}, "6603561103": {"Name": "Ghamande S.", "AuthorID": "6603561103", "AffiliationID": "60105348", "AffiliationName": "Augusta University, Georgia Regents University)"}, "7006077011": {"Name": "Birrer M.J.", "AuthorID": "7006077011", "AffiliationID": "60027086", "AffiliationName": "University of Alabama at Birmingham"}, "7202106192": {"Name": "Fleming G.F.", "AuthorID": "7202106192", "AffiliationID": "60011092", "AffiliationName": "University of Chicago Medicine"}, "7004611662": {"Name": "Markham M.J.", "AuthorID": "7004611662", "AffiliationID": "60013959", "AffiliationName": "University of Florida"}, "23992081700": {"Name": "Hirte H.W.", "AuthorID": "23992081700", "AffiliationID": "60007594", "AffiliationName": "Juravinski Cancer Centre"}, "7003694463": {"Name": "Provencher D.M.", "AuthorID": "7003694463", "AffiliationID": "60009657, 60009507", "AffiliationName": "Centre Hospitalier de l'Universite de Montreal, Universite de Montreal"}, "12753875500": {"Name": "Basu B.", "AuthorID": "12753875500", "AffiliationID": "60031101, 60016390", "AffiliationName": "Department of Oncology, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust"}, "8771515300": {"Name": "Kristeleit R.", "AuthorID": "8771515300", "AffiliationID": "60022148", "AffiliationName": "Cancer Institute, University College London, UCL"}, "7404407261": {"Name": "Armstrong D.K.", "AuthorID": "7404407261", "AffiliationID": "60021212", "AffiliationName": "Johns Hopkins Kimmel Cancer Center"}, "56963358200": {"Name": "Schwartz B.", "AuthorID": "56963358200", "AffiliationID": "124030922", "AffiliationName": "Northwell Health Gynecologic Oncology"}, "7003978104": {"Name": "Braly P.", "AuthorID": "7003978104", "AffiliationID": "101556580", "AffiliationName": "Women's Cancer Care"}, "16444338600": {"Name": "Hall G.D.", "AuthorID": "16444338600", "AffiliationID": "60020454", "AffiliationName": "St James University Hospital"}, "7003877617": {"Name": "Nephew K.P.", "AuthorID": "7003877617", "AffiliationID": "60134856, 60021121, 60018927", "AffiliationName": "Indiana University, School of Medicine, IU Simon Cancer Center"}, "57191252794": {"Name": "Jueliger S.", "AuthorID": "57191252794", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals"}, "56797931200": {"Name": "Oganesian A.", "AuthorID": "56797931200", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals Inc."}, "57147626300": {"Name": "Naim S.", "AuthorID": "57147626300", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals Inc."}, "56797235900": {"Name": "Hao Y.", "AuthorID": "56797235900", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals Inc."}, "57202302918": {"Name": "Keer H.", "AuthorID": "57202302918", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals Inc."}, "54966498900": {"Name": "Azab M.", "AuthorID": "54966498900", "AffiliationID": "60111951", "AffiliationName": "Astex Pharmaceuticals Inc."}, "8748256100": {"Name": "Matei D.", "AuthorID": "8748256100", "AffiliationID": "60013227, 60007363", "AffiliationName": "Northwestern University, Feinberg School of Medicine"}}}